Nationwide coverage of molecular drug susceptibility testing in patients with pulmonary multidrug/rifampicin-resistant tuberculosis in South Korea: a retrospective cohort study (2015-2021).

Although all institution types exhibited an increasing trend in coverage over time, mDST coverage in small hospitals, primary clinics and long-term care hospitals remained at 71.0% in 2021 ( figure 3 and online supplemental table S2 ).

also in 63,971 other papers